NOVEL REGULATORY MECHANISMS CONTROLLING BONE REPAIR AND OSTEOPOROSIS

控制骨修复和骨质疏松的新型调节机制

基本信息

项目摘要

DESCRIPTION (provided by applicant): Osteoporosis is a disease that is characterized by low bone mass that results in insidious deterioration of the skeleton leaving it fragile and vulnerable to fracture. Osteoporosis is due to multiple genetic, hormonal, nutritional, and physical factors that act alone or together to diminish skeletal integrity. Estrogen replacement blunts the loss of bone by blocking osteoclast-mediated bone demineralization. In this setting, parathyroid hormone (PTH) is able to mediate bone growth. We recently made a series of observations that suggest another potentially important mechanism by which estrogen deficiency may contribute to osteoporosis. Specifically, we found that amino-terminally truncated PTH fragments that are thought to be inactive promoted rapid internalization of the PTH receptor (PTH1R) in a cell-specific manner in bone. These otherwise biologically inactive PTH fragments reduced the abundance of PTH1R on the cell surface without first activating the receptor. This uncoupling of PTH1R activation and inactivation is due to the presence of a cytoplasmic adaptor protein, termed EBP50 (ezrin-binding protein, 50 kDa). EBP50 contains an estrogen response element. Experimental animals lacking EBP50 have osteopenia and develop osteoporosis. We hypothesize that estrogens increase EBP50 expression, thereby protecting the osteoblast PTH1R against the inactivating effects of PTH fragments. The Specific Aims of this project are: (1) To examine gonadal hormone regulation of EBP50, and (2) to determine if estrogen induction of EBP50 expression contributes to restoring the anabolic action of PTH on bone. The effects of gonadal hormones on EBP50 expression will be determined in osteoblastic human and rat cell lines. The second group of experiments consists of two parts. In the first, ectopic ossicles prepared from bone marrow of EBP50-null mice will be used as a model system to analyze the effects of PTH and estrogens on bone, independent of systemic effects or the donor animal. The second part will examine the effects of estradiol administration alone or in combination with PTH on restoring bone in ovariectomized EBP50-null mice. The proposed studies will lead to a better understanding of the hormonal events that impact bone health and importantly influence the response to bone loading. Novel predictive measures of fragility and potential avenues for therapeutic intervention may be developed. The goal of these new studies is to characterize how the effect of female hormones on bone may be regulated by a certain adapter protein. The long-term objective is to identify novel compounds that can be used to treat post-menopausal osteoporosis.
描述(由申请人提供):骨质疏松症是一种以低骨量为特征的疾病,其导致骨骼的隐性退化,使其变得脆弱并易于骨折。骨质疏松症是由于多种遗传、激素、营养和物理因素单独或共同作用而降低骨骼完整性。雌激素替代通过阻断破骨细胞介导的骨脱矿作用来减缓骨丢失。在这种情况下,甲状旁腺激素(PTH)能够介导骨生长。我们最近进行了一系列的观察,提示雌激素缺乏可能导致骨质疏松症的另一个潜在的重要机制。具体而言,我们发现,氨基末端截短的PTH片段,被认为是无活性的促进快速内化的PTH受体(PTH1R)在骨细胞特异性的方式。这些在其他方面没有生物活性的PTH片段减少了细胞表面上PTH1R的丰度,而没有首先激活受体。这种PTH1R激活和失活的解偶联是由于胞质衔接蛋白的存在,称为EBP 50(ezrin结合蛋白,50 kDa)。EBP 50含有雌激素反应元件。缺乏EBP 50的实验动物具有骨质减少并发展成骨质疏松症。我们假设雌激素增加EBP 50的表达,从而保护成骨细胞PTH1R免受PTH片段的失活作用。本研究的具体目的是:(1)研究性激素对EBP 50的调节作用,(2)确定雌激素诱导EBP 50表达是否有助于恢复PTH对骨的合成代谢作用。将在人和大鼠成骨细胞系中测定性腺激素对EBP 50表达的影响。第二组实验由两部分组成。首先,将从EBP 50缺失小鼠的骨髓制备的异位小骨用作模型系统,以分析PTH和雌激素对骨的影响,与全身效应或供体动物无关。第二部分将研究雌二醇单独或与PTH联合给药对卵巢切除EBP 50缺失小鼠骨恢复的影响。拟议的研究将有助于更好地了解影响骨骼健康的激素事件,并对骨负荷的反应产生重要影响。新的预测措施的脆弱性和潜在的治疗干预的途径可能会开发。这些新研究的目标是描述女性激素对骨骼的影响如何受到某种衔接蛋白的调节。长期目标是确定可用于治疗绝经后骨质疏松症的新型化合物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Peter A Friedman其他文献

Peter A Friedman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Peter A Friedman', 18)}}的其他基金

RGS14 Regulation of Hormone-sensitive NPT2A-mediated Phosphate Transport
RGS14 激素敏感 NPT2A 介导的磷酸盐转运的调节
  • 批准号:
    10618970
  • 财政年份:
    2021
  • 资助金额:
    $ 18.56万
  • 项目类别:
RGS14 Regulation of Hormone-sensitive NPT2A-mediated Phosphate Transport
RGS14 激素敏感 NPT2A 介导的磷酸盐转运的调节
  • 批准号:
    10317557
  • 财政年份:
    2021
  • 资助金额:
    $ 18.56万
  • 项目类别:
RGS14 Regulation of Hormone-sensitive NPT2A-mediated Phosphate Transport
RGS14 激素敏感 NPT2A 介导的磷酸盐转运的调节
  • 批准号:
    10450178
  • 财政年份:
    2021
  • 资助金额:
    $ 18.56万
  • 项目类别:
Functional Polarity of PTH Receptor Signaling: Cellular and Molecular Mechanisms
PTH 受体信号传导的功能极性:细胞和分子机制
  • 批准号:
    9978053
  • 财政年份:
    2017
  • 资助金额:
    $ 18.56万
  • 项目类别:
Functional Polarity of PTH Receptor Signaling: Cellular and Molecular Mechanisms
PTH 受体信号传导的功能极性:细胞和分子机制
  • 批准号:
    9380356
  • 财政年份:
    2017
  • 资助金额:
    $ 18.56万
  • 项目类别:
BINDING CAPACITY OF THE PDZ2 DOMAIN OF NHERF1
NHERF1 的 PDZ2 结构域的结合能力
  • 批准号:
    8364320
  • 财政年份:
    2011
  • 资助金额:
    $ 18.56万
  • 项目类别:
COMPLEX FORMATION AND BINDING AFFINITY OF NHERF1 TO C-TERMINAL PEPTIDES
NHERF1 与 C 端肽的复合物形成和结合亲和力
  • 批准号:
    8364344
  • 财政年份:
    2011
  • 资助金额:
    $ 18.56万
  • 项目类别:
EBP50 REGULATION OF PTH RECEPTOR IN BONE AND KIDNEY
EBP50 对骨和肾中 PTH 受体的调节
  • 批准号:
    7903700
  • 财政年份:
    2009
  • 资助金额:
    $ 18.56万
  • 项目类别:
NOVEL REGULATORY MECHANISMS CONTROLLING BONE REPAIR AND OSTEOPOROSIS
控制骨修复和骨质疏松的新型调节机制
  • 批准号:
    7447840
  • 财政年份:
    2007
  • 资助金额:
    $ 18.56万
  • 项目类别:
EBP50 REGULATION OF PTH RECEPTOR IN BONE AND KIDNEY
EBP50 对骨和肾中 PTH 受体的调节
  • 批准号:
    7049700
  • 财政年份:
    2006
  • 资助金额:
    $ 18.56万
  • 项目类别:

相似国自然基金

APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Novel regulatory mechanisms controlling hepatic apoB-Lp lipid loading and secretion
控制肝脏apoB-Lp脂质负荷和分泌的新调控机制
  • 批准号:
    10628991
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
CAREER: De novo emergence of novel regulatory mechanisms that determine carbon and nitrogen resource allocations in plants
职业生涯:决定植物碳氮资源分配的新型调控机制从头出现
  • 批准号:
    2238942
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Continuing Grant
Identification of regulatory mechanisms operating in rare pathogenic astrocyte subsets in multiple sclerosis with a novel genomic technology
利用新型基因组技术鉴定多发性硬化症中罕见致病性星形胶质细胞亚群的调节机制
  • 批准号:
    10737509
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
Uncovering novel mechanisms and potential therapeutic targets for IgA vasculitis through GWAS and systems-level analysis of regulatory networks.
通过 GWAS 和调节网络的系统级分析揭示 IgA 血管炎的新机制和潜在治疗靶点。
  • 批准号:
    10723651
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
Novel regulatory mechanisms and agonists of STING
STING 的新颖调控机制和激动剂
  • 批准号:
    10655761
  • 财政年份:
    2023
  • 资助金额:
    $ 18.56万
  • 项目类别:
Elucidation of immune checkpoint regulatory mechanisms and development of novel therapies
免疫检查点调节机制的阐明和新疗法的开发
  • 批准号:
    22K20798
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Deciphering the specificity and molecular mechanisms of regulatory T cells using novel approaches
使用新方法破译调节性 T 细胞的特异性和分子机制
  • 批准号:
    10576791
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
Investigating Novel Regulatory Mechanisms of the Cardiac Calcium Pump by Inhibitory and Stimulatory Micropeptides.
通过抑制性和刺激性微肽研究心脏钙泵的新调节机制。
  • 批准号:
    10537189
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
Innate immune responses and IL-27: novel regulatory mechanisms of TLR7 expression and signaling
先天免疫反应和 IL-27:TLR7 表达和信号传导的新调节机制
  • 批准号:
    RGPIN-2017-04526
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
    Discovery Grants Program - Individual
Genomic strategies to identify novel gene regulatory mechanisms by ligand-activated transcriptional enhancers
通过配体激活转录增强子识别新基因调控机制的基因组策略
  • 批准号:
    10354014
  • 财政年份:
    2022
  • 资助金额:
    $ 18.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了